Nurix Therapeutics, Inc. NRIX Proceeds from disposition of marketable securities and other investments
Proceeds from disposition of marketable securities and other investments at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s proceeds from disposition of marketable securities and other investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s proceeds from disposition of marketable securities and other investments?
- Nurix Therapeutics, Inc. (NRIX) reported proceeds from disposition of marketable securities and other investments of $133.15M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s proceeds from disposition of marketable securities and other investments changed year-over-year?
- Nurix Therapeutics, Inc.'s proceeds from disposition of marketable securities and other investments decreased by 4.3% year-over-year, from $139.2M to $133.15M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s proceeds from disposition of marketable securities and other investments?
- Over 3 years (2021 to 2024), Nurix Therapeutics, Inc.'s proceeds from disposition of marketable securities and other investments has grown at a 24.4% compound annual growth rate (CAGR), from $238.91M to $459.51M.